USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS BY CARDIOLOGISTS SINCE THE RELEASE OF 2022 AHA/ACC/HFSA GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE

• Main Authors: Gowtham R. Grandhi, MD MPH (Author), Rishav Adhikari, MD (Author), Erfan Tasdighi, MD (Author), Albert D. Osei, MD MPH (Author), Michael Khorsandi, MD (Author), Anurag Mehta, MD (Author), Michael Blaha, MD MPH (Author)
• Format: Book
• Published: Elsevier, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Therapeutic Area: Heart Failure Background: Several studies have shown that most patients who are eligible for an Sodium-glucose Cotransporter-2 inhibitor (SGLT2i) are not receiving them and the proportion of prescriptions from cardiologists was very low (<2%) as of December 2020. Moreover, two S...